Vijaya Diagnostic Centre IPO: key dates, price band 2021

Vijaya Diagnostic Centre’s main-board IPO was a book-built issue aggregating up to about ₹1,894 crore, structured entirely as an offer for sale (OFS) by existing shareholders. Because it was a pure OFS, the proceeds were slated to go to selling shareholders rather than the company. The bidding window opened on September 1, 2021 and closed on September 3, 2021, with the basis of allotment finalised on September 8, 2021. Shares were listed on both the BSE and NSE on September 14, 2021.

The IPO drew attention for its detailed category allocation, an anchor book that raised ₹566.12 crore, and post-issue implied market capitalisation cited at ₹5,414 crore at the upper end of the price band. The issue also carried an employee reservation with a per-share discount.

IPO structure: pure offer for sale

The Vijaya Diagnostic Centre IPO was described as a book build issue of ₹1,894.43 crore and also cited as aggregating to ₹1,894.26 crore in the offer document-style summary. The entire issue was an offer for sale of 3,56,88,064 equity shares (3.57 crore shares) of face value ₹1 each.

The selling shareholders and OFS split were stated as: 5,098,296 shares aggregating to ₹270.61 crore by Dr. S. Surendranath Reddy (promoter selling shareholder), 29,487,290 shares aggregating to ₹1,565.13 crore by Karakoram Limited, and 1,102,478 shares aggregating to ₹58.52 crore by Kedaara Capital Alternative Investment Fund (Kedaara Capital AIF 1).

Key IPO dates: bidding, allotment and listing

Bidding for the IPO ran from Wednesday, September 1, 2021 to Friday, September 3, 2021. The basis of allotment was finalised on Wednesday, September 8, 2021. Refund initiation was indicated for September 9, 2021, and credit of shares to demat accounts was indicated for September 13, 2021. The listing on BSE and NSE took place on Tuesday, September 14, 2021.

The anchor investor bid date was August 31, 2021. Anchor lock-in details were also provided for 30 days and 90 days tranches.

Price band, issue price and lot size

The price band for Vijaya Diagnostic Centre IPO was fixed at ₹522 to ₹531 per share, with the final issue price at ₹531 per share. The lot size was 28 shares, and bids could be placed for a minimum of 28 shares and in multiples thereafter.

Minimum retail application amount was stated as ₹14,868 at the cut-off price in the application table, while another summary line cited ₹14,616 as the minimum investment for 28 shares. The same document set also listed retail, sNII, and bNII investment amounts based on lots and shares.

Investor categories and share allocation

The IPO offered a detailed allocation split by category. Total shares offered were 3,56,88,064 (100%). The allocation was described as 1,77,69,031 shares (49.79%) for QIB, 53,30,710 shares (14.94%) for NII, and 1,24,38,323 shares (34.85%) for retail (RII). Within QIB, 1,06,61,418 shares (29.87%) were shown as allocated to anchor investors and 71,07,613 shares (19.92%) to QIB (ex-anchor).

A separate summary also stated that 50% of the issue was reserved for QIBs, with 15% for non-institutional investors and 35% for retail investors.

Anchor book: amount raised and lock-in dates

The IPO raised ₹566.12 crore from anchor investors, with the anchor bid date on Tuesday, August 31, 2021. The number of shares offered in the anchor portion was stated as 1,06,61,418.

Lock-in end dates were specified as October 8, 2021 for 50% of the anchor shares (30 days) and December 7, 2021 for the remaining shares (90 days).

Employee reservation and discount

The issue included a reservation of up to 1,50,000 shares for employees, with an employee discount of ₹52 per share to the issue price. The employee reservation portion was also described as aggregating up to ₹7.19 crore and constituting up to 0.15% of the post-offer paid-up equity share capital.

The category rules also indicated cut-off bidding was allowed for RII (up to ₹2 lakh) and for employee applications, with separate guidance for combined employee plus RII/NII bidding.

Subscription details and grey market indicator

The ₹1,895-crore IPO was reported as subscribed 4.54 times during September 1 to September 3. Category-wise subscription figures were stated as: QIB oversubscribed 13.07 times, non-institutional investors 1.32 times, retail 1.09 times, and the employees’ portion at 98% subscription.

Grey market premium (GMP) was reported at ₹5, implying a grey market trading price of ₹536 against the expected issue price of ₹531 per share.

Listing and early trading: price data on BSE and NSE

Trading data shared for the stock after listing included the final issue price of ₹531 on both BSE and NSE. The listed open was cited as ₹542.30 on BSE and ₹540.00 on NSE. The day’s low was cited as ₹533.65 on BSE and ₹532.50 on NSE, while the day’s high was cited as ₹650.75 on BSE and ₹648.00 on NSE.

The “last trade” values shown were ₹619.30 (BSE) and ₹620.10 (NSE) in the provided price details.

Company snapshot: footprint and services

Established in 1981, Vijaya Diagnostic Centre was described as one of the fastest-growing diagnostic chains in Southern India. It provides a one-stop solution for pathology and radiology testing services, alongside nuclear medicine, radiology, laboratory services, health check-ups and medical services.

The network was stated as 81 diagnostic centres and 11 reference laboratories across 13 cities, with presence mentioned in Telangana and Andhra Pradesh, as well as the National Capital Region and Kolkata. Test offerings were listed as around 740 routine tests, 870 specialised pathology tests, 220 basic tests, and 320 advanced radiology tests. Another operational snapshot noted an employee strength of 2,200 and about 2.63 million customers served till March 31, 2021, along with NABH patient safety accreditation and NABL accreditation.

Key intermediaries and investor process

Edelweiss Financial Services Ltd. was named as a book running lead manager in one summary, while another section listed ICICI Securities, Edelweiss Financial Services and Kotak Mahindra Capital Company as book-running lead managers. Kfin Technologies Ltd. (KFintech) was identified as the registrar.

For allotment status, investors were directed to check either the registrar’s portal (KFintech) or the BSE website using details such as application number, PAN, or depository identifiers. The timeline provided also indicated refunds around September 9 and demat credit around September 13.

Key facts table

Market impact: what the numbers say

Because the IPO was entirely an OFS, the capital raised was described as going to the promoter and investor selling shareholders, rather than funding new corporate expansion directly through fresh issue proceeds. Subscription was reported at 4.54 times overall, with the strongest demand coming from QIBs at 13.07 times, while retail demand was shown at 1.09 times and NII at 1.32 times.

In the secondary market data shared, the stock opened above the issue price on both exchanges and recorded an intraday high of ₹650.75 on BSE and ₹648.00 on NSE. The last traded prices provided were ₹619.30 on BSE and ₹620.10 on NSE.

Analysis: why this IPO stood out

The disclosed allocation structure highlighted the central role of institutional demand, including the anchor book that raised ₹566.12 crore. The lock-in schedule provided explicit dates for release of anchor shares, which investors often track after listing.

Operationally, the company’s business profile was positioned around integrated diagnostics, with a large test menu and a network spanning 13 cities via diagnostic centres and reference labs. The issue also included a defined employee reservation with a ₹52 discount, which was accompanied by an employees’ subscription figure of 98%.

Conclusion

Vijaya Diagnostic Centre’s IPO was priced at ₹531 per share, ran from September 1-3, 2021, and listed on September 14, 2021, with the entire issue structured as an OFS of 3,56,88,064 shares. The anchor book raised ₹566.12 crore, and category subscription data showed strong QIB demand compared with retail and NII participation. Investors tracking the post-listing process had clear dates for allotment finalisation, refunds, demat credit, and anchor lock-in expiries as outlined in the issue details and timelines.